Grifols soars 14% on the stock market after announcing a plan to invoice €10 billion in 2029

Although a year ago, when Grifols reported record revenues Its stock fell to a decade lowThis year, the exact opposite has happened: the Catalan pharmaceutical company's shares have shot up by 14%. However, behind this volatility is the same cause: the presentation to analysts.